ADC Therapeutics SA (ADCT), a Swiss commercial-stage biotechnology company pioneering antibody-drug conjugates (ADCs), is covered by a small but divided group of analysts. The three most current, individually attributed targets produce a mean of $4.00: RBC Capital's Leonid Timashev holds a $2.00 target with a Hold rating (maintained in October 2026 after a June downgrade from Outperform), while Guggenheim's Michael Schmidt reiterated Buy at $5.00 in August 2026 (down from $10) and Stephens reiterated Buy at $5.00 in June 2026 (down from $8). HC Wainwright, which previously carried an $8 target, downgraded the stock to Neutral in June 2026 and dropped its target.
The $2.00-to-$5.00 spread is wide and reflects genuine disagreement: cautious voices argue the safety overhang caps the stock, while bullish analysts see the valuation and pipeline as undervaluing an approved, revenue-generating product. Some data aggregators citing up to five analysts report a slightly lower average near $3.33, underscoring that the aggregate is an arithmetic calculation, not a guarantee or an official published consensus.
ADCT trades near $1.58, with a 52-week range of roughly $0.78 to $4.98. Reaching the $4.00 central target would therefore require an advance of about 153% — a very large move that would return the shares near their recent 52-week high.
The stock crashed about 66% in the weeks after the June 2026 topline readout of the Phase 3 LOTIS-5 trial, which met its primary endpoint of progression-free survival but showed elevated Grade 5 treatment-emergent adverse events (13.2% versus 4.6% for control) and no overall-survival benefit. Since that reset, the shares have partially recovered. The path to $4.00 would likely require resolving the regulatory uncertainty, delivering favorable LOTIS-7 data, and rebuilding commercial momentum for ZYNLONTA (loncastuximab tesirine-lpyl), the company's CD19-directed ADC approved for relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
Several factors could underpin a recovery. The company held $219.1 million in cash as of June 30, 2026, with a runway extending into at least 2028, reducing near-term dilution risk. A 17% workforce reduction should yield roughly $10 million in annual savings. LOTIS-7, evaluating ZYNLONTA with glofitamab, enrolled 100 patients at the selected dose with full data expected in the fourth quarter of 2026; a favorable readout could reframe the benefit-risk debate. ZYNLONTA's existing accelerated-approval monotherapy indication also continues to generate revenue — $18.6 million in Q2 2026 — providing a commercial foundation most development-stage peers lack.
The principal obstacle is regulatory. At an August 2026 pre-submission meeting, the FDA expressed "substantial concerns" about LOTIS-5's benefit-risk profile and verification of the treatment benefit, prompting the company to reassess the path toward an sBLA (supplemental Biologics License Application). The elevated fatal-adverse-event signal, largely infection-driven and concentrated in patients aged 75 and older, could delay or narrow any label expansion into earlier lines of DLBCL. Persistent losses, modest revenue growth, and execution risk around LOTIS-7 all represent additional hurdles.
The shares sit well above the 52-week low near $0.78, where buyers stepped in after the post-LOTIS-5 selloff, and well below the $4.98 high. The $2.00 level — the low end of the analyst range and a psychological round number — marks the first meaningful resistance, while $4.00 and $5.00 represent progressively higher zones. A sustained move above $2.00 would likely be needed to shift the longer-term trend structure from recovery to genuine re-rating.
Analyst price targets generally reflect a roughly 12-month research horizon, though firms do not always state one explicitly and timelines vary. Investors should watch the full LOTIS-7 data (expected Q4 2026), any updated regulatory strategy for LOTIS-5 and a possible sBLA submission, the American Society of Hematology presentations, quarterly ZYNLONTA revenue trends, and cash-burn trajectory. Further analyst revisions — which have trended downward this year — would also signal shifting sentiment.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals as market conditions, technical behavior, and AI-driven analysis change. Traders can use these signals to discover opportunities, keep an eye on existing positions, and spot shifting trends more efficiently than manual screening allows. For anyone tracking a volatile name such as ADCT, automated signal monitoring can help flag changes in momentum before they become obvious in the headlines.
The $4.00 central target reflects the average of three current, verifiable analyst targets across a wide $2.00-to-$5.00 range, and represents a very large 153% move from the current price near $1.58. The bull case rests on cash runway, an approved product, and a potentially favorable LOTIS-7 readout, while the bear case centers on the FDA's LOTIS-5 safety concerns and the risk of a delayed or narrowed label expansion. With such a wide spread of targets and a binary clinical catalyst ahead, the outcome depends heavily on regulatory and data events rather than valuation alone. Investors should monitor LOTIS-7 data, the regulatory path, and analyst revisions rather than treat the mean target as a forecast.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, ADCT has been loosely correlated with QTTB. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if ADCT jumps, then QTTB could also see price increases.
| Ticker / NAME | Correlation To ADCT | 1D Price Change % | ||
|---|---|---|---|---|
| ADCT | 100% | -9.58% | ||
| QTTB - ADCT | 45% Loosely correlated | -0.11% | ||
| CLRB - ADCT | 43% Loosely correlated | -4.69% | ||
| SEPN - ADCT | 37% Loosely correlated | +3.15% | ||
| AXON - ADCT | 36% Loosely correlated | -0.21% | ||
| RCUS - ADCT | 35% Loosely correlated | -1.48% | ||
More | ||||
| Ticker / NAME | Correlation To ADCT | 1D Price Change % |
|---|---|---|
| ADCT | 100% | -9.58% |
| Pharmaceuticals category (151 stocks) | 1% Poorly correlated | -0.67% |
| Pharmaceuticals: Generic category (81 stocks) | 0% Poorly correlated | -0.76% |